The next CRCL/CLB seminar will take place Friday the 5th of may, at 11.30am in the ONCORA meeting room (Centre Léon Bérard, 2nd floor). We are pleased to welcome Pr Cathrin Brisken (EPFL Lausanne). More information will be available soon.
Save the date : 4th ANRS HBV Cure Workshop
May 16th 2017 - Espace Saint-Martin - 75003 Paris -
Preliminary program click here
The 3rd CRCL Symposium will welcome you on the 25th-27th September 2017 ! More information on our website here.
MANY THANKS !
The 1st International Symposium "Immune Responses in Cancer and Infection" jointly organized by the CRCL and the CIRI (International Research Centre in Infectiology) took place recently in Lyon. It was a great pleaser to welcome 20 international speakers as well as a total of 380 participants! We thank our sponsors and partners which help us to organize this event! Many thanks again.
We can still access to the final program: click here
Follow the CRCL news on Twitter!
A stemness-related ZEB1-MSRB3 axis governs cellular pliancy and breast cancer genome stability
11 April 2017
Morel AP et al. Nature Medecine Avril 2017 (CRCL team of Alain Puisieux).
Chromosomal instability (CIN), a feature of most adult neoplasms from their early stages onward, is a driver of tumorigenesis. However, several malignancy subtypes, including some triple-negative breast cancers, display a paucity of genomic aberrations, thus suggesting that tumor development may occur in the absence of CIN. Here we show that the differentiation status of normal human mammary epithelial cells dictates cell behavior after an oncogenic event and predetermines the genetic routes toward malignancy. Whereas oncogene induction in differentiated cells induces massive DNA damage, mammary stem cells are resistant, owing to a preemptive program driven by the transcription factor ZEB1 and the methionine sulfoxide reductase MSRB3. The prevention of oncogene-induced DNA damage precludes induction of the oncosuppressive p53-dependent DNA-damage response, thereby increasing stem cells' intrinsic susceptibility to malignant transformation. In accord with this model, a subclass of breast neoplasms exhibit unique pathological features, including high ZEB1 expression, a low frequency of TP53 mutations and low CIN.
PubMed access: click here
Structural Decoding of the Netrin-1/UNC5 Interaction and its Therapeutical Implications in Cancers
25 March 2016
This study involves the team of Patrick Mehlen.
Netrin-1 has been shown to be up-regulated in a fraction of human cancers as a mechanism to allow these tumors to escape the pro-apoptotic activity of some of its main dependence receptors, the UNC5 homologs (UNC5H). Here we identify the V-2 domain of netrin-1 to be important for its interaction with the Ig1/Ig2 domains of UNC5H2. We generate a humanized anti-netrin-1 antibody that disrupts the interaction between netrin-1 and UNC5H2 and triggers death of netrin-1-expressing tumor cells in vitro. We also present evidence that combining the anti-netrin-1 antibody with epidrugs such as decitabine could be effective in treating tumors showing no or modest netrin-1 expression. These results support that this antibody is a promising drug candidate.
PubMed access: click here
Communiqué de presse : SANOFI-INSERM HBV Cure program: a medical, academic and pharmaceutical alliance for research on Hepatitis B. Cliquez ici
Création d'un Laboratoire International Associé (LIA) entre l'équipe CRCL d'Alain Puisieux "EMT et plasticité des cellules cancéreuses" et l'équipe de Frédéric Hollande "Molecular Mechanisms of Tumour Progression" du Victorian Comprehensive Cancer Centre (Université de Melbourne, Australie).
There are several positions available at the CRCL: click here
A postdoc position in onco-immunology is available in C. Caux's lab : click here
Postdoc in tumor immunology: click here
A postdoc position in the team of F. Zoulim : click here
Other positions 2016
- Other postdoc positions are available in the teams of M. Gabut and J. Marie: click here